Dr. David Goldstein
Dr. David Goldstein serves as Professor of Genetics and Development in the College of Physicians and Surgeons and Director of the Institute for Genomic Medicine at Columbia University (NY). He is an investigator and key advisor for CURE’s Epilepsy Genetics Initiative, a groundbreaking project dedicated to advancing epilepsy genetics. David is also a member of Epi4K, an international consortium of doctors, scientists and researchers working together to further our understanding of the genetic basis of epilepsy. He received a Ph.D. in Biological Sciences from Stanford University.
Dr. Orrin Devinsky
Dr. Orrin Devinsky is the Director of the NYU Comprehensive Epilepsy Center and the Saint Barnabas Institute of Neurology and Neurosurgery (INN). He is also a Professor of Neurology, Neurosurgery and Psychiatry at NYU Langone School of Medicine. Orrin specializes in epilepsy and behavioral neurology. He received a B.S. and M.S. from Yale University and an M.D. from Harvard Medical School.
Dr. Matthew Might
Dr. Matthew Might is the Director of the Hugh Kaul Precision Medicine Institute at the University of Alabama at Birmingham (UAB) School of Medicine. There, he leverages his expertise in genomics and informatics to drive the Institute’s strategic direction. Formerly, Matthew served as a member of the White House’s Precision Medicine Initiative and was an Associate Professor in the School of Computing at the University of Utah. He received a CAREER Award from the National Science Foundation, and in 2014 he was appointed one of six Presidential Scholars at the University of Utah. Matthew received a Ph.D. in Computer Science from Georgia Institute of Technology. His son, Bertrand, was the first patient ever discovered with a rare disorder known as N-Glycanase deficiency. Matt posted an essay online that catalyzed the creation of the NGLY1 patient community, the remarkable aftermath of which has been chronicled in publications such as The New Yorker and Der Spiegel.
Dr. Steven Petrou
Professor Steven Petrou is a Deputy Director and co-Head of the Division of Epilepsy at the Florey Institute of Neuroscience and Mental Health at the University of Melbourne, Australia. He leads the Laboratory of Ion Channels and Human Disease, a multidisciplinary team of researchers with a focus on revealing fundamental mechanisms of disease genesis in the central nervous system. Current major areas of investigation center on the development and characterization of genetically engineered mouse models for the study of human epilepsy. Steven also serves on the editorial board of the Journal Neurobiology of Disease, as an associate editor at PLOS Genetics, and as a member of the Genetics Commission of the International League Against Epilepsy. Steven received a BSc(Hons) and a Ph.D. from the University of Melbourne.
Dr. Slavé Petrovski
Dr. Slavé Petrovski currently serves as Vice President and Head of Genome Analytics at AstraZeneca’s Center for Genomics Research. In this position, he leads efforts to uncover novel insights from genome sequencing that could be used to advance AstraZeneca’s drug discovery efforts. Prior to this role, Slavé led the Computational Genomics group at the University of Melbourne, where he still pursues his research interests as Honorary Associate Professor. He has received multiple awards and grants, including the National Health and Medical Research Council’s CJ Martin & Career Development Fellowships. Slavé earned a Ph.D. in Bioinformatics and Biostatistics from the University of Melbourne, Australia.
Mark Flynn is Co-Managing Partner of GSV Asset Management and the President of GSV Capital, a publicly traded fund focused on identifying and investing in rapidly growing late stage venture capital-backed private companies. Previously, Mark managed Trilogy Capital Partners, a Menlo Park California based private investment and consulting firm, since its formation in 1997. Prior to forming Trilogy, he worked in various capacities in the investment banking groups at Salomon Brothers and Volpe, Brown & Whelan. Mark has served as chairman of The Preserve Company, and as a member of the board of directors of the DAPER Fund at Stanford University as well as a number of privately held companies. He holds an M.B.A. from Harvard Business School, is a C.P.A., and received a B.A. from Saint John’s University in Collegeville, Minnesota.